ReviewJournal of education and health promotion2025
MODY: Strategies for a unique form of diabetes.
Review in Journal of education and health promotion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hnf1aos1 as a Metabolic Coordinator of Hepatic Lipid Homeostasis and Feedback Control.Non-coding RNA · 2026Article
- Prediction of maturity-onset diabetes of the young subtypes using machine learning.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maturity-onset diabetes of the young (MODY) is a monogenic, autosomal dominant form of diabetes that typically presents before the age of 25. It is caused by mutations in single genes involved in insulin production and glucose regulation, leading to various subtypes, including Hepatocyte Nuclear Factor 1 Alpha-MODY (HNF1A-MODY), Glucokinase-MODY (GCK-MODY), Hepatocyte Nuclear Factor 4 Alpha-MODY (HNF4A-MODY), and Hepatocyte Nuclear Factor 1 Beta-MODY (HNF1B-MODY), each with unique clinical characteristics and treatment responses. For instance, HNF1B-MODY is often associated with renal anomalies, while HNF1A and HNF4A subtypes commonly respond well to sulfonylureas. Unlike Type 1 and Type 2 diabetes, MODY usually manifests as mild to moderate hyperglycemia, making tailored treatment essential. Genetic testing plays a critical role in diagnosis, guiding personalized management strategies that may include specific medications, lifestyle adjustments, and vigilant monitoring to mitigate complications. Preventive care, routine health check-ups, and comprehensive patient education are crucial for effective MODY management, ultimately enhancing the quality of life for individuals living with this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.